Tel: +1 (844) 792-6300
The FDA has granted Thrombolex 510(k) clearance for its Bashir Endovascular Catheter, a device used to manage the infusion of fluids.
The device is used by physicians to control the infusion of specific fluids, such as thrombolytics, into a patient’s peripheral vasculature system—veins and arteries not in the chest and abdomen.
The system includes six expandable mini-infusion catheters, allowing the physician to deliver specified fluids in specific locations within the vasculature.
New Britain, PA, May 4, 2026 — Thrombolex, Inc., a medical device company dedicated to advancing minimally invasive endovascular treatment of venous thromboembolism (VTE), today announced the enrollment of the 100th patient in the RAPID-PE clinical study. This...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a...
New Britain, PA - (October 28th, 2025) - Thrombolex, Inc. presented the prespecified interim analysis from the first 50 patients in RAPID-PE, a prospective, multicenter U.S. study evaluating On-The-Table (OTT) pharmaco-mechanical lysis (PML) without any post procedure...